Pfizer Inc. (PFE) reached a settlement and license agreement with Mylan Inc. (MYL) regarding a generic version of Vfend tablets, allowing the generic drug maker to begin marketing the antifungal medication in the U.S. starting in the first quarter of 2011.

The details of the agreement weren't disclosed. The accord is subject to review by the Department of Justice and the Federal Trade Commission.

It was the latest setback for Pfizer, which has struggled to bring new drugs to market to offset lost revenue from patent expirations for current best-sellers. Pfizer, maker of blockbuster cholesterol drug Lipitor and erectile-dysfunction drug Viagra, is acquiring Wyeth partly to beef up research efforts.

Mylan's Matrix Laboratories Ltd. (524794.BY) unit in August 2008 notified Pfizer that it had filed an abbreviated new drug application with the Food and Drug Administration, challenging four of Pfizer's patents relating to antifungal Vfend, which expire between 2009 and 2016.

The drug, voriconazole, can be administered orally or intravenously and can be used to treat esophageal candidiasis and a number of other serious fungal infections. The generics to be sold by Mylan had U.S. sales of $164 million in the year ended June 30.

Pfizer shares were up 1.1% at $16.97 in recent premarket trading amid a broad rally. Mylan shares closed Tuesday at $16.37 and didn't trade premarket.

 
   -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com;